摘要 |
<p>Disclosed is an anticonvulsant pharmaceutical composition useful for treating migraine via nasal administration having binding affinities for the receptor sites viz. GABA-A agonist site, Glutamate-AMPA site, Glutamate-Kainate site, Glutamate-NMDA agonistic site, Glutamate-NMDA glycine (strychnine insensitive) site and sodium channel (site 2), comprising: an aqueous, alcoholic or hydroalcoholic extract comprising a mixture of triterpenoid saponins derived from the pericarp of the fruit of Sapindus trifoliatus, and pharmaceutically acceptable additives, wherein the concentration of the triterpenoid saponins is calculated as hederaginin, said hederagenin amounting to 0.001 to 1.0 (% w/v) of the anticonvulsant pharmaceutical composition. Also disclosed is an aqueous, alcoholic or hydroalcoholic extract comprising a mixture of triterpenoid saponins derived from the pericarp of the fruit Sapindus trifoliatus, wherein the triterpenoid saponins contain hederagenin and wherein the concentration of the triterpenoid saponins is calculated as a concentration of 4 to 8% w/w hederagenin, and a method of preparing the extract.</p> |